Objective: To assess if health-related quality of life (HRQOL) of children with chronic kidney disease (CKD) and different comorbid conditions can be identified based on the EQ-5D child-friendly version (EQ-5D-Y). Design: Prospective cross-sectional study. Setting: A tertiary care medical center in Taiwan. Study participants: All CKD patients aged 7-18 years treated at the center between May 2014 and December 2016. Main Outcome Measures: HRQOL assessment was done using EQ-5D-Y. Spearman correlation tests were used for construct validity of the traditional Chinese version of EQ-5D-Y. Test-retest reliability was determined through Cohen's kappa values and intraclass correlation coefficients (ICC). Laboratory results and CKD-related morbid conditions were ascertained and assessed their associations with HRQOL score using multivariate linear regression. Results: Of 68 participants, 53 of them completed two HRQOL assessments of HRQOL at least 6-month. Cross-sectional analysis revealed fair to moderate correlations between EQ visual analogue score and patient characteristics. Older children at assessment (P < 0.01), girls (P = 0.03) and presence of mineral bone disorders had a significantly negative impact on HRQOL. Children self-reported EQ-5D-Y dimensions were found to be fairly to highly reliable (kappa = 0.2 to 0.8), except for 'pain/discomfort' and 'anxiety/depression'. Conclusions: The EQ-5D-Y discriminated among children with different level of CKD-related clinical burden, but the psychometric properties may be limited in some HRQOL dimensions. Further research will need to address factors that may threaten validity and reliability data provided by children and adolescents.
Introduction
Chronic kidney disease (CKD) is a major public health issue worldwide. Children and adolescents with CKD have increased risk of premature death from cardiovascular disease and end-stage renal disease requiring renal replacement therapy (RRT) such as dialysis and kidney transplantation. Various studies report a prevalence of RRT ranging from 18 to 100 cases per million of the aged-related pediatric population [1] . Progression of CKD is associated with a number of complications in children, including hypertension, hyperlipidemia, anemia, osteodystrophy, growth retardation and impaired neurocognitive development.
Health-related quality of life (HRQOL) assessments of treatments for childhood conditions are increasingly regarded as crucial end points in clinical trials, and are being gradually introduced into day-to-day clinical practice. In childhood CKD, HRQOL assessments have focused on pediatric patients with end-stage renal disease and underwent renal replacement therapy [2] [3] [4] [5] . Children with CKD reported poorer overall HRQOL score (Pediatric Inventory of Quality of Life Core Scales, PedsQL) and poorer physical, school, emotional and social domain scores compared to healthy children [6] . Short stature was associated with significantly lower scores in the physical functioning in different children populations [7, 8] , and adverse effects on psychosocial development and quality of life [9] . Identifying risk factors for CKD progression and its adverse effect on HRQOL unique to children is as important as treatment in children with CKD-associated complications.
The EQ-5D is most widely used generic measure of HRQOL used for economic evaluations of health care interventions, but it is not designed for use in children. The EQ-5D-Y, adapted the descriptive health classification system of the standard EQ-5D intended for completion in adults. As of now, the internationally applicable child-friendly version EQ-5D-Y has been established by the EuroQol group and translated into many different languages [10, 11] . Value sets for the EQ-5D-Y are currently under development. In the interim, there is opportunity to understand the measurement properties of the EQ-5D-Y in terms of construct validity and reliability. To date, no studies have been performed in kidney disease using the EQ-5D-Y in children. The aims of this study were two-fold: (i) to assess HRQOL in pediatric patients with mild-to-moderate CKD states as measured by the visual analogue scale (VAS) and descriptive system of the EQ-5D-Y; (ii) to investigate the validity and reliability of Taiwanese version of EQ-5D-Y.
Methods

Patients and study settings
Children and adolescents with CKD were recruited in a prospective cross-sectional study (Clinical Trials ID: NCT02022046) from a tertiary medical center in Taiwan. This study was reviewed and approved by the Institutional Review Board of Chang Gung Memorial Hospital, Taoyuan, Taiwan (IRB 1015107A3). Participation in the project required written informed consent by the children adolescents and by his or her parents after written and oral information about the study.
EQ-5D-Y
The Taiwan pilot version of EQ-5D-Y was interviewer administered to children with CKD aged 7-18 years. The standard EQ-5D-Y consists of a descriptive system that includes five dimensions. They are (i) mobility; (ii) self-care; (iii) usual activities; (iv) pain/discomfort; and (v) anxiety/depression. Each dimension has three levels, representing severity: no problems, some problems and a lot of problems. The instrument also includes a visual analogue scale (VAS), which is anchored at 100 (best imaginable health) and 0 (worst imaginable health) to represent the overall health status rated by the participant [10] .
Data collection
One trained interviewer administered the questionnaires to children and adolescents with CKD in a separated room next to the doctor's room. EQ-5D-Y was measured with a baseline visit and follow-up visits at 6-month intervals. Patients with enough information to assess kidney function, clinical conditions close to the date of EQ-5D-Y measure were included in analysis. The unit of observation in this study was a study visit with the composited assessment of EQ-5D-Y and comorbid conditions; thus, an individual could contribute more than one observation.
Kidney function was assessed by determining estimated glomerular filtration rate (eGFR) from serum creatinine using Schwartz bedside equation [12] . Proteinuria was defined as urine total protein divided by urine creatinine >150 mg/g [13] , and hyperlipidemia in children was identified based on total cholesterol, triglycerides or LDL [14] . Anemia was defined as hemoglobin (Hb) <5th percentile using age-and sexspecific norms [15] . Elevated blood pressure (BP) was defined as systolic or diastolic BP > the 90th percentile for age, sex and height [16] , whereas high normal BP was defined as systolic or diastolic BP between the 50th and 90th percentile. Mineral bone disorder was defined by serum phosphate multiplied with serum calcium ≥6.5 mg/dL for children <13 years old and >5.5 mg/dL for children >13 years [17] . Hyperuricemia was defined by serum uric acid (SUA) level using ageand gender-specific norm. Using age-and gender-specific norm, growth retardation was defined as body height or body weight <3rd percentile [18] , and overweight was defined using body mass index (BMI) [19] .
Statistical analyses
Continuous data were presented as means with standard deviations (SD), and categorical data were presented as numbers and percentages. Construct validity was assessed by testing for a significant difference in mean VAS score among patients with the presence of comorbid conditions. It was hypothesized that participants with more CKD-related conditions should have a significant lower HRQOL preference score (i.e. EQ VAS score) than the healthier group. An unadjusted analysis assessed the univariate association between EQ-5D-Y domains, levels of eGFR, and comorbidity using Spearman's Rho (γs) correlation tests. Correlation of 0.5 or above were considered strong, 0.35-0.5 moderate, 0.2-0.34 poor and below than 0.2 as absent [20] . To further investigate the impacts of different health status on EQ-5D-Y, a linear regression model was used to examine the difference in mean VAS score with the adjustment for gender, age and presence of clinical conditions. The results are presented as estimates of beta (β) with 95 % confidence intervals (CI).
Test-retest reliability of the EQ-VAS was assessment using Intraclass Correlation Coefficients (ICCs). Cohen's unweighted, kappa coefficient (κ) of agreement between the children's responses for EQ-5D-Y 5 dimensions, tested 6 months apart used to assess testretest reliability. The κ value <0.2 indicates as slight agreement, 0.21-0.40 as fair agreement, 0.41-0.60 as moderate agreement, 0.61-0.80 as substantial agreement and kappa >0.80 as almost perfect agreement [21] . Thus, an ICC >0.8 was considered as almost perfect reliability [22] . All analyses were performed using SAS version 9.3 (SAS Institute Inc, Cary, NC, United States). The criterion for statistical significance was a two-tailed P value of <0.05.
Results
Social-demographic and clinical data
A total of 68 children and adolescents aged 7-18 years were recruited with 121 observations in a 2.5-year follow-up period. Over 78% (n = 53) participants had 2 EQ-5D-Y measures, 3 n = number of participants or number of assessments in clinical conditions during the study period; LDL = low density lipoprotein; Hb = hemoglobin; SUA = serum uric acid.
withdrawn and 3 were administratively censored at December, 2016, 8 missed the scheduled appointment and 2 moved to another city before end of study. EQ-5D-Y dimensions and VAS Figure 1 presents the distribution within the 5 dimensions of EQ-5D-Y. Between 92.56% and 97.52% of participants reported no problems with 'self-care', 'morbidity' and 'usual activities', 84.3% to 85.95% experienced no problems with 'pain/discomfort' and 'happiness/worry/sadness'. The proportion of EQ-5D-Y measures with no problems in all dimensions (11 111) was 67.8%, and 4.2% with worst health states (32 211, 31 211, 31 121, 22 211) (Fig. 2 ). Table 2 shows results of correlations between five dimensions, VAS of EQ-5D-Y and patient-level characteristics. The correlations between 'morbidity', self-care' and 'usual activities' domains were more likely in the moderate range (0.3 ≤ γs ≤ 0.5) with the presence of growth retardation, anemia and proteinuria. The majority of correlations of some clinical conditions were negatively associated with EQ VAS value (γs, −0.02 to −0.28), but not eGFR (proxy of renal function).
Validity
Statistically significant correlations (0.19 ≤ γs ≤ 0.28) were found between the number of comorbid conditions and EQ VAS value, but not in any individual dimension, indicating EQ VAS also affected by other factors beyond the 5 dimensions of health status. Nevertheless, more comorbid conditions had negatively effects on EQ VAS, indicating that VAS of EQ-5D-Y could be able to distinguish between children with specific comorbid conditions in different CKD disease status. Table 3 shows that age over than 13 years, girls and presence of mineral bone disorder were significantly associated with worsening EQ-5D-Y among pediatric patients with mild-to-moderate CKD.
Reliability
The test-retest reliability was based on the 53 children and adolescents who completed two EQ-5D-Y assessments (n = 53). Table 4 shows the Cohen's κ value for 'mobility' and 'self-care' dimensions were in the high level of agreement, while 'usual activities' was within fair agreement. The 'pain/discomfort' and 'anxiety/depression' dimensions fell within slight to no agreement. The ICC value for mean EQ VAS value was 0.47 (0.08-0.69).
Discussion
As EQ-5D-Y has been tested and accepted as reliable measure in many pediatric populations with and without health conditions, we tested it's Spearman's correlation coefficients (H0:rs = 0); *P < 0.05; **P < 0.01; ***P < 0.001. validities for outcomes research in Taiwanese youth. The study results show that although a high proportion of pediatric patients with no problems in any of the EQ-5D-Y dimensions, additional analyses suggested that the EQ-5D-Y is associated with pediatric patients with a range of chronic CKD-related conditions in practice setting. In this study, the lower EQ VAS value was correlated with poor health states and more comorbid conditions. Significantly fair to moderate correlations were found between some clinical conditions and 5 EQ-5D-Y dimensions (except for 'pain/discomfort'). It seems that children and adolescents with mild-to-moderate CKD were able to respond appropriately to the EQ-5D-Y, reporting actual impact of their health conditions on quality of life. Comorbid condition is very important factor in determining HRQOL of pediatric patients with dialysis [23] , but their impacts on HRQOL remains uncertain among children with CKD. For instance, the lack of association was found between hypertension and HRQOL in children with mild-to-moderate CKD using PedsQL [24] . It has been suggested that symptoms of hypertension include headache, trouble sleeping and tiredness were not easily specific to hypertension within the domains of HRQOL instruments [25] . For CKD-related medical conditions that were not covered in the quality of life domains, the EQ VAS value provides a suitable complementary indicator to assess preference-based HRQOL from pediatric patient's perception.
Consistent with previous study results, adolescent groups tended to report more problems than younger groups in 'pain/discomfort' and 'anxiety/depression' dimensions of the EQ-5D-Y [11, 26] . Multivariate regression model showed that adolescents (>13 years) were more likely to have a lower EQ VAS than younger children. Nevertheless, the proportion of EQ-5D-Y measures with problems was lower in 'pain/ discomfort' (14%) and 'anxiety/depression' (15.5%) dimensions among study participants than in other countries (20-39% and 15.1-45.8%, respectively) [11, [27] [28] [29] [30] . This difference could be associated with ethnic differences [31] .
Based on conventional interpretation guides for test-retest reliability [21, 22] , the EQ-5D-Y was fair to almost perfect agreement in the dimensions of 'usual activities', 'self-care', 'mobility' and EQ VAS value. The test-retest test was conducted over a 6-month interval. It is expected that health would not have changed in such a short period of time, but long enough to ensure that participants would not remember their initial measurement. Of concern was the lack of consistency in the 'pain/discomfort' and 'anxiety/depression' dimensions. It is possible that participants have been relating to a specific event on the date of EQ-5D-Y measures (today's health status). For instance, fear of having laboratory tests, feeling being sick and negative emotions (sad, anger, self-esteem and confidence), and social relationships (school, family) may impact children's perception of the extent of deviation in the 'anxiety/depression' dimension. Our data reveal that teenagers (aged 13-15 years) had a greater negative effect on EQ VAS than those participants aged over 15 years.
Although the sample size was small across age groups in the present study, the disagreement on anxiety/depression' (n = 17) was slightly higher in participants aged <13 years (33.3%) than those aged 13 and above (30%). For the disagreement on 'pain/discomfort' dimension (n = 12), older children were more observed than that of young participants (24% and 19%, respectively). In organ transplantation studies, lower quality of life was found in children who had transplantation at young age [32, 33] ; after transplantation, adolescents reported concern about their health, less pleasure than ordinary adolescents and poor social functioning with peers [33] , and negative emotions and impaired psychosocial functioning were found correlated with older age at assessment [32] . Further research is required to investigate different levels of disease severity and the age effects on the changes in physical and psychosocial dimensions of EQ-5D-Y.
Comorbidity is common in children and adolescents with mild-tomoderate stage of CKD. Other researchers have observed that children with mild to moderate CKD have lower scores of physical, school, emotional and social in PedsQL domains than their healthy counterparts [6] . The largest differences from healthy youth were in school functioning possibly due to the complexities of medical care and frequencies of medical visits interfering with school attendance and role activities. Similar to previous results, no differences was found based on the stage of CKD (eGFR) in the overall scale. These observations underscore the impact of CKD on children's HRQOL has not only on morbidity but also the variables of family functioning, relationship with friends and environments such as school relevant for children. Chronic illnesses can persistent several years and have a negative impact on child's quality of life during developmental ages. It is critical to ensure HRQOL instruments have demonstrated sensitivity to change in health due to skills, attitudes and priorities characteristic of child development over a period time with the child's age [34] . Longitudinal analysis of HRQOL is needed and is an ongoing aim of our childhood CKD study (Clinical Trials ID: NCT03227055).
Different HRQOL instruments reflect different theoretical bases and their content are designed to capture differences on numbers of dimensions of physical, emotional, mental and social functioning for children with chronic illnesses or specific medical interventions [35] . Currently, no CKD-specific instrument for children has been established although PedsQL has been used in pediatric patients with CKD and most in children undergo dialysis. Of concern is that EQ-5D-Y instrument does not include environmental factors such as relationships with family, peers and community. It would be desirable to incorporate EQ-5D-Y with other validated HRQOL instruments (e.g. PedsQL) for children with mild/moderate CKD in order to identify children's needs and to provide improved care. Additionally, the single center study included only limited patients who were able to attend our research clinic; the results might not generalizable to the most affected children and adolescents with CKD. However, as age and prevalent clinical conditions in the present study revealed similar patterns with a recent study conducted in multicenter settings [36] , this limitation seems to be acceptable.
Conclusions
The study results support moderate correlations between the different dimensions and the VAS of the EQ-5D-Y and comorbid conditions for children and adolescents with mild-to-moderate CKD. The EQ-5D-Y can be considered an acceptable valid generic HRQOL which reflects differences in health according to the CKD-related comorbid conditions. Further a larger, longitudinal study for children and adolescents with mild-to severe CKD is warrant to measure the changes in different levels of comorbidity control and status of renal disease.
